Sirius Therapeutics has snapped up nearly $50 million in a Series B2 financing round that saw existing investors OrbiMed, Creacion Ventures, and Hankang Capital re-up, according to a release on Tuesday.
The Series B2 round was led by an undisclosed corporate venture capital firm. New investor Shanghai-based BioTrack Capital, which invests in early-stage biotech, medtech, and healthcare firms, also joined the round, per the release.
The proceeds will be used to advance clinical development of Sirius’s novel siRNA therapeutics for cardiometabolic disorders and the innovation of its next-generation RNA delivery technologies.
Founded in 2021, Sirius, with an innovation centre in the US and a translational medicine centre in China, previously secured $60 million in a Series B funding round led by Hankang Capital in October 2023.
The fresh funding has brought the firm’s total capital raised to $150 million, per the release.
Qunsheng Ji, CEO of Sirius Therapeutics, said that the firm currently has three clinical-stage programmes, with the most advanced one set to begin Phase II clinical trials in Europe.
SRSD107—the most advanced compound—is a long-acting, next-generation anticoagulant for thromboembolic disorders, in which blood clots get stuck in the blood vessels and lead to blockage.
Biotech firms in China raised a total of $328.2 million through the completion of 23 deals in Q1 2025, according to DealStreetAsia’s proprietary data. The deal count was similar to the 26 deals recorded in Q4 2024; however, the deal value marked a 60% growth compared to $205.6 million in Q4.
